Menlo Park, CA – March 20th, 2025 — Deepcell, a leader in AI-driven single-cell analysis and sorting, today announces a know-how agreement with Mayo Clinic to develop next-generation technology aimed at enhancing efficiency and accuracy in in vitro fertilization (IVF). Through this collaboration, Deepcell seeks to enhance its proprietary REM-I platform to better evaluate and sort cells, to ultimately improve patient outcomes and expand access to advanced fertility treatments.
A critical aspect of IVF involves selecting and preparing the most viable cells for successful fertilization. Current methods often rely on manual inspection under a microscope—an approach that can be time-consuming and subject to human bias. Deepcell’s REM-I platform integrates advanced artificial intelligence and microfluidics to assess cellular characteristics without the need for labels or dyes. By refining its AI algorithms with Mayo Clinic’s clinical insights and research expertise, the REM-I platform aims to significantly reduce variability and streamline IVF procedures.
“Our collaboration with Mayo Clinic unites their extensive clinical knowledge with Deepcell’s proprietary AI-based approach,” said Maddison Masaeli, CEO at Deepcell. “By focusing on consistent, data-driven cell assessment, our REM-I platform strives to elevate the precision of IVF processes, with the goal of ultimately improving success rates and broadening accessibility of IVF.”
Deepcell seeks to roll out the REM-I platform to IVF clinics worldwide, with the goal of enabling healthcare professionals to operate more consistently and effectively.
For more information about Deepcell’s REM-I platform, please visit www.deepcell.com.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
About Deepcell
Deepcell is a leading AI-driven cell analysis company dedicated to revolutionizing single-cell research and clinical applications. Its REM-I platform integrates cutting-edge imaging and microfluidics technology, empowering researchers and healthcare professionals with highly accurate, label-free cell analysis and sorting capabilities. Deepcell’s innovative solutions aim to significantly reduce the complexity and cost of cellular research and diagnostics.
Media Contacts
info@deepcellbio.com
